Shoulder Innovations to Showcase Growth Strategy at Key Investor Meeting

GRAND RAPIDS, Mich. – February 18, 2026 – Shoulder Innovations, Inc. (NYSE: SI), a medical technology firm focused exclusively on the shoulder surgery market, announced today it will present at the upcoming Canaccord Genuity 2026 Musculoskeletal Conference. The presentation, scheduled for March 3, offers a critical platform for the company to detail its growth strategy and technological advancements to an influential audience of investors and analysts, just one week before its fourth-quarter and full-year 2025 earnings release.

A High-Stakes Pitch to the Investment Community

The Canaccord Genuity conference is a premier event for growth-oriented companies in the orthopedic sector, making this a significant opportunity for Shoulder Innovations. For a company that went public via an Initial Public Offering in July 2025, such presentations are vital for building and maintaining investor confidence in a competitive market. The event is designed to connect innovative firms with institutional investors, and the company's management will have a prime opportunity to articulate its long-term vision.

Investors will be watching closely. The company's recent performance paints a picture of rapid expansion coupled with the significant costs of scaling a commercial operation. In its third-quarter 2025 results, Shoulder Innovations reported a remarkable 58% year-over-year increase in net revenue to $11.8 million, driven by a 53% surge in the sale of its implant systems. This strong top-line performance prompted the company to raise its full-year 2025 revenue guidance to a range of $45 million to $46 million, signaling confidence in its commercial momentum.

However, this growth has come at a price. Selling, general, and administrative expenses rose 78% to $15.1 million in the same quarter, contributing to a net loss and a reported EPS of -$0.48, which missed analyst consensus. As an "emerging growth company" under SEC rules, such losses are not uncommon during a commercial ramp-up. Investors at the conference will be keen to understand the company’s path to profitability and how its "disruptive ecosystem" and differentiated commercial model can capture market share efficiently and drive long-term value.

Tapping a Multi-Billion Dollar Market

Shoulder Innovations is competing in a large and expanding market. The global shoulder arthroplasty market was valued at approximately $1.76 billion in 2025 and is projected to more than double to $3.68 billion by 2035, expanding at a compound annual growth rate of nearly 8%. This growth is fueled by powerful demographic and clinical trends. An aging global population is leading to a higher incidence of degenerative joint diseases like osteoarthritis, a primary driver for shoulder replacement procedures.

Furthermore, increased awareness of treatment options, a rise in sports-related injuries, and advancements in surgical techniques are encouraging more patients to seek solutions for chronic shoulder pain and dysfunction. The market itself is also undergoing a significant procedural shift. The use of reverse total shoulder arthroplasty (rTSA) has surged, offering better outcomes for patients with complex conditions like rotator cuff tear arthropathy. Another key trend is the migration of procedures from traditional hospitals to more cost-effective Ambulatory Surgical Centers (ASCs). This shift places a premium on procedural efficiency and predictable outcomes, playing directly into the strategy Shoulder Innovations is championing. While the market includes orthopedic giants like Stryker and Zimmer Biomet, specialized players see an opportunity to innovate and capture share by addressing specific unmet needs.

Beyond the Implant: A Holistic Surgical Ecosystem

Shoulder Innovations' core strategy hinges on what it calls its "ecosystem," a comprehensive approach that extends beyond the physical implant. The company asserts that this integrated system is designed to solve "long-standing clinical and operational challenges" that have historically complicated shoulder surgery. This holistic view is central to its pitch as a market transformer rather than just another device manufacturer.

At the heart of the ecosystem are its advanced implant systems, such as the InSet™ platform, which recently gained FDA 510(k) clearance for fracture indications. However, the company emphasizes that the implant is just one piece of the puzzle. The system integrates preoperative planning software to help surgeons prepare for complex cases, efficient and simplified instrument systems to streamline the procedure itself, and specialized support to ensure consistent execution. This combination is intended to reduce the learning curve and improve reproducibility.

This model is designed to create value for every stakeholder in the care chain. For surgeons, the promise is greater predictability and procedural simplicity, reducing surgical variability and potentially improving patient outcomes. For hospitals and ASCs, the focus on efficiency can translate into shorter operating times, reduced sterilization costs, and better alignment with value-based care models that reward quality and cost-effectiveness. For patients, the ultimate goal is more reliable pain relief and a faster return to daily activities. By fostering surgeon-to-surgeon collaboration, the company also aims to build a community of practice that accelerates learning and the adoption of best practices.

Innovating for Efficiency and Outcomes

Looking ahead, Shoulder Innovations is betting on continued innovation to solidify its market position. The company's exclusive focus on the shoulder allows it to direct its research and development resources toward solving specific problems in the field, a key differentiator from larger, more diversified competitors. This targeted approach is evident in its recent strategic partnership, announced in late 2025, to co-develop a micro-robotic shoulder arthroplasty platform.

A move into robotics signals an ambition to be at the forefront of technological advancement in orthopedics. Robotic assistance in joint replacement has the potential to enhance precision, improve implant placement, and further standardize procedures, which could lead to even more predictable outcomes. This forward-looking investment aligns with broader industry trends toward digital surgery, data analytics, and personalized medicine, positioning the company for the next evolution of surgical care.

As the healthcare system continues its inexorable shift toward value, the company's emphasis on delivering efficiency across all sites of care—from major hospitals to outpatient surgery centers—becomes increasingly relevant. The upcoming presentation will be a key moment for management to articulate how this blend of a robust commercial engine, a holistic product ecosystem, and a forward-thinking innovation pipeline will enable Shoulder Innovations to carve out a significant and profitable space in the competitive orthopedic landscape.